These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 14531041)

  • 21. The role of DAT-SPECT in movement disorders.
    Kägi G; Bhatia KP; Tolosa E
    J Neurol Neurosurg Psychiatry; 2010 Jan; 81(1):5-12. PubMed ID: 20019219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dopamine transporter imaging.
    Lees AJ; Grosset DG
    Mov Disord; 2003 Oct; 18 Suppl 7():S1-2. PubMed ID: 14531038
    [No Abstract]   [Full Text] [Related]  

  • 23. Role of dopamine transporter imaging in routine clinical practice.
    Marshall V; Grosset D
    Mov Disord; 2003 Dec; 18(12):1415-23. PubMed ID: 14673877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Parkinson Study Group.
    Neurology; 2000 Nov; 55(10):1540-7. PubMed ID: 11094111
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nigrostriatal dopamine terminal imaging with dopamine transporter SPECT: an update.
    Tatsch K; Poepperl G
    J Nucl Med; 2013 Aug; 54(8):1331-8. PubMed ID: 23864718
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism.
    Booij J; Tissingh G; Winogrodzka A; van Royen EA
    Eur J Nucl Med; 1999 Feb; 26(2):171-82. PubMed ID: 9933352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Objective measures for the progression of Parkinson's disease.
    Snow B
    J Neurol Neurosurg Psychiatry; 2003 Mar; 74(3):287. PubMed ID: 12588908
    [No Abstract]   [Full Text] [Related]  

  • 28. Nuclear Imaging in the Diagnosis of Clinically Uncertain Parkinsonian Syndromes.
    Buchert R; Buhmann C; Apostolova I; Meyer PT; Gallinat J
    Dtsch Arztebl Int; 2019 Nov; 116(44):747-754. PubMed ID: 31774054
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The diagnostic value of dopamine transporter imaging and olfactory testing in patients with parkinsonian syndromes.
    Georgiopoulos C; Davidsson A; Engström M; Larsson EM; Zachrisson H; Dizdar N
    J Neurol; 2015 Sep; 262(9):2154-63. PubMed ID: 26122543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: part 1. Baseline and 3-month observations.
    Benamer HT; Oertel WH; Patterson J; Hadley DM; Pogarell O; Höffken H; Gerstner A; Grosset DG
    Mov Disord; 2003 Sep; 18(9):977-84. PubMed ID: 14502664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PET and SPECT functional imaging studies in Parkinsonian syndromes: from the lesion to its consequences.
    Thobois S; Jahanshahi M; Pinto S; Frackowiak R; Limousin-Dowsey P
    Neuroimage; 2004 Sep; 23(1):1-16. PubMed ID: 15325346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined DaT imaging and olfactory testing for differentiating parkinsonian disorders.
    Borghammer P; Knudsen K; Østergaard K; Danielsen EH; Pavese N; Arveschoug A; Bluhme H; Bode M; Morsing A
    Int J Clin Pract; 2014 Nov; 68(11):1345-51. PubMed ID: 24754902
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Not Available].
    Prange S; Hermier M; Danaila T; Laurencin C; Thobois S
    Presse Med; 2017 Mar; 46(2 Pt 1):202-209. PubMed ID: 28040345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. 2000.
    Parkinson Study Group
    Neurology; 2001 Nov; 57(10 Suppl 3):S52-9. PubMed ID: 11775602
    [No Abstract]   [Full Text] [Related]  

  • 35. Evaluation of patients with Clinically Unclear Parkinsonian Syndromes submitted to brain SPECT imaging using the technetium-99m labeled tracer TRODAT-1.
    Felicio AC; Godeiro-Junior C; Shih MC; Borges V; Silva SM; Aguiar Pde C; Hoexter MQ; Barsottini OG; Andrade LA; Bressan RA; Ferraz HB
    J Neurol Sci; 2010 Apr; 291(1-2):64-8. PubMed ID: 20096859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Nuclear neuroimaging of dopamine transporter in Parkinsonism--role in routine clinical practice].
    Cohenpour M; Golan H
    Harefuah; 2007 Sep; 146(9):698-702, 733. PubMed ID: 17969308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Experience with 123I-Iodobenzamide in the differential diagnosis of Parkinson's disease and Parkinson-plus disease].
    Paniagua Correa C; García Alonso P; Balsa Bretón MA; Mariana Monguía A; Penín González FJ; Pey Illera C
    Rev Esp Med Nucl; 2010; 29(2):57-62. PubMed ID: 20133020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters.
    Fischman AJ; Bonab AA; Babich JW; Palmer EP; Alpert NM; Elmaleh DR; Callahan RJ; Barrow SA; Graham W; Meltzer PC; Hanson RN; Madras BK
    Synapse; 1998 Jun; 29(2):128-41. PubMed ID: 9593103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes.
    Vlaar AM; van Kroonenburgh MJ; Kessels AG; Weber WE
    BMC Neurol; 2007 Sep; 7():27. PubMed ID: 17764571
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease.
    Booij J; Habraken JB; Bergmans P; Tissingh G; Winogrodzka A; Wolters EC; Janssen AG; Stoof JC; van Royen EA
    J Nucl Med; 1998 Nov; 39(11):1879-84. PubMed ID: 9829575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.